生殖系CDKN2A致病性变异携带者的胰腺癌监测:20年前瞻性随访的检出率与结局
该研究分析了347例生殖系CDKN2A致病性变异携带者接受胰腺癌监测(每年MRI/MRCP,可选EUS)的前瞻性数据,中位随访5.6年。31例(8.9%)诊断胰腺导管腺癌(PDAC),至70岁累积发病率为20.7%,12例(33.3%)为I期,原发PDAC中位生存26.8个月,5年生存率32.4%。结论认为监测可检出早期PDAC并改善可切除性和生存。
要点
- 347例CDKN2A致病性变异携带者中31例(8.9%)诊断PDAC,至70岁累积发病率为20.7%。
- 36例PDAC中30例(83.3%)影像学评估可切除,12例(33.3%)为I期。
- 原发PDAC中位生存26.8个月,5年生存率32.4%(95%CI 19.1–54.8)。
核心结论
- 长期监测研究显示CDKN2A致病性变异携带者PDAC发病率高,监测可检出早期PDAC并改善可切除性和生存。
研究设计与样本
- 前瞻性收集参加胰腺癌监测的CDKN2A生殖系致病性变异携带者数据,共347例。
- 监测方案为每年一次磁共振成像联合磁共振胆胰管成像,并可选内镜超声。
- 中位随访5.6年(四分位距2.3–9.9年)。
主要发现
- 31例(8.9%)患者诊断36例PDAC,诊断中位年龄60.4岁(四分位距51.3–64.1岁)。
- 原发PDAC至70岁累积发病率为20.7%。
- 5例(5/31,16.1%)携带者诊断第二原发PDAC。
- 36例PDAC中30例(83.3%)在影像学评估时被认为可切除,12例(12/36,33.3%)为I期。
- 原发PDAC诊断后中位生存26.8个月,5年生存率32.4%(95%CI 19.1–54.8);接受切除者(22/31,71.0%)5年总生存率44.1%(95%CI 27.2–71.3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pancreatic cancer surveillance in high-risk individuals may lead to detection of pancreatic ductal adenocarcinoma (PDAC) at an earlier stage and with improved survival. This study evaluated the yield and outcomes of 20 years of prospective surveillance in a large cohort of individuals with germline pathogenic variants (PVs) in CDKN2A. METHODS: Prospectively collected data were analyzed from individuals participating in pancreatic cancer surveillance. Surveillance consisted of annual magnetic resonance imaging with magnetic resonance cholangiopancreatography and optional endoscopic ultrasound. RESULTS: Three hundred forty-seven germline PV carriers participated in surveillance and were followed for a median of 5.6 (interquartile range 2.3-9.9) years. A total of 36 cases of PDAC were diagnosed in 31 (8.9%) patients at a median age of 60.4 (interquartile range 51.3-64.1) years. The cumulative incidence of primary PDAC was 20.7% by age 70 years. Five carriers (5 of 31; 16.1%) were diagnosed with a second primary PDAC. Thirty (83.3%) of 36 PDACs were considered resectable at the time of imaging. Twelve cases (12 of 36; 33.3%) presented with stage I disease. The median survival after diagnosis of primary PDAC was 26.8 months, and the 5-year survival rate was 32.4% (95% CI, 19.1 to 54.8). Individuals with primary PDAC who underwent resection (22 of 31; 71.0%) had an overall 5-year survival rate of 44.1% (95% CI, 27.2 to 71.3). Nine (2.6%; 9 of 347) individuals underwent surgery for a suspected malignant lesion, which proved to not be PDAC, and this included five lesions with low-grade dysplasia. CONCLUSION: This long-term surveillance study demonstrates a high incidence of PDAC in carriers of a PV in CDKN2A. This provides evidence that surveillance in such a high-risk population leads to detection of early-stage PDAC with improved resectability and survival.
引用
- Klatte DCF, Boekestijn B, Wasser MNJM, et al. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. J Clin Oncol. 2022. PMID: 35658523. doi:10.1200/JCO.22.00194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。